BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)

HR 9495, FY2027 appropriations for DOD, specifically provisions related to medical research; HR 9260, FY2027 appropriations for HHS, specifically provisions related to medical research;

HR 9495, FY2027 appropriations for DOD, specifically provisions related to medical research; HR 9260, FY2027 appropriations for HHS, specifically provisions related to medical research; HR 7173, Follow the Science Act; S 4494, American Cures Act; HR 9632, Accelerating Innovation (AI) for Kids with Cancer Act; OMB Proposed Uniform Grants Regulation; Policies to enable international collaboration by NIH grantees; Policies to maintain the NIHs incremental grant funding model;

HR 247 / S 46, Health Care Affordability Act; S 2420, No Surprises Act Enforcement Act; HR 3521, the Clinical Trial Modernization Act; HR 5526, Biosimilar Red Tape Elimination Act; HR 5582, S 2355, the Patients Deserve Price Tags Act; HR 6248 / S 4027, Healthy Competition for Better Care Act HR 6485 / S 43, Skinny Labels, Big Savings Act; HR 6867 / S 3562, NIH Clinical Trial Integrity Act; HR 7895, the PBM Kickback Prohibition Act; HR 8908, the STOP GAMES Act; HR 9393, Lower Costs, More Transparency Act; HR 9396, the Prior Authorization Accountability Act; HR 9397, the Premium Transparency Act; HR 9661, Expedited Access to Biosimilars Act; S 1041, Affordable Prescriptions for Patients Act; S 1095, Stop STALLING Act; S 1096, Preserve Access to Affordable Generics & Biosimilars Act S 1097, Interagency Patent Coordination & Improvements Act; S 2658, Medication Affordability & Patent Integrity Act; S 3014, Ensuring Timely Access to Generics Act; S 4509, Patients Before Monopolies Act; Policies to address the expiration of the enhanced Advanced Premium Tax Credits; Policies to improve transparency in hospital and insurer costs and finances; Policies to streamline pediatric patient access to subspecialist care via telemedicine; Policies to protect patients and consumers from junk insurance, including short-term limited duration insurance; Policies related to the modernization of clinical trials; Policies related to the 2027 FDA user fee agreements; Implementation of the No Surprises Act; Policies related to oversight of insurance agents and brokers; Oversight and patient impact of the 340B program;

HR 3514, Improving Seniors Timely Access to Care Act; HR 5243, a bill to increase data transparency for supplemental benefits under Medicare Advantage; HR 9392, Medicare Advantage Cost Transparency Act; S 1105, No UPCODE Act; S 1629, Same Care, Lower Cost Act; S 1936, Improving Access to Transfusion Care for Patients Act; S 4886, Medicare Cost Cap Act; CMS Interim Final Rule on Medicaid work requirements; Regulatory and legislative proposals to expand site-neutral payment in Medicare; Implementation of the Accelerating Kids Access to Care Act (HR 1509, S 752); Regulatory proposals related to most-favored-nation drug pricing;